Floatz logo

Imgn632

Blastic Plasmacytoid Dendritic Cell Neoplasm

AbbViePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the Blastic Plasmacytoid Dendritic Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Tagraxofusp
French Innovative Leukemia Organisation
Phase 2BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2BB
Fludarabine
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2B

View all 48 →

Same molecule, other indications

Imgn632 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
56 / 100
View asset →
myeloproliferative neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
mixed phenotype acute leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →